Acquisition target Evofem reported revenue of $7.8 million for the six months ended June 30, 2024 Acquisition target Appili has received approximately $6.0 million of the total $14.0 million to...
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development...
Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will...
Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it had...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Definitive agreement with Aditxt, if approved by Appili shareholders, provides significant premium to shareholders and resources to advance key programs ATI-1701 funding commitments from U.S. Air...
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -16.6666666667 | 0.03 | 0.035 | 0.025 | 152698 | 0.02969853 | CS |
4 | -0.005 | -16.6666666667 | 0.03 | 0.035 | 0.025 | 88912 | 0.02983407 | CS |
12 | -0.01 | -28.5714285714 | 0.035 | 0.045 | 0.025 | 73430 | 0.03319845 | CS |
26 | -0.02 | -44.4444444444 | 0.045 | 0.05 | 0.025 | 118590 | 0.03700201 | CS |
52 | -0.025 | -50 | 0.05 | 0.06 | 0.025 | 130676 | 0.03768309 | CS |
156 | -0.985 | -97.5247524752 | 1.01 | 1.03 | 0.025 | 186543 | 0.10805142 | CS |
260 | -1.105 | -97.7876106195 | 1.13 | 1.6 | 0.025 | 166612 | 0.27933151 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관